Masultab

Amisulpride, the active ingredient in Masultab, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia and acute psychotic episodes in adult patients. GNH USA supplies Masultab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Amisulpride is an atypical antipsychotic used within the schizophrenia and psychosis therapeutic pathway. - Schizophrenia: reduces positive and negative psychotic symptoms and helps maintain long‑term stability. - Acute psychotic episodes: alleviates sudden onset of hallucinations, delusions and agitation. - Maintenance therapy for schizophrenia: supports ongoing symptom control and relapse prevention.

Amisulpride may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Weight gain: modest increase in body weight. - Extrapyramidal symptoms: tremor, rigidity or restlessness.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements after prolonged use. - Severe hypotension: marked drop in blood pressure, especially on standing. - Agranulocytosis: dangerous reduction in white blood cells, increasing infection risk.

Before initiating Masultab, clinicians should consider several safety measures. - Monitor for extrapyramidal symptoms: assess movement disorders regularly. - Assess cardiac function: evaluate QT interval and baseline ECG. - Use caution in renal impairment: adjust dose if renal function is reduced. - Avoid abrupt discontinuation: taper gradually to minimise withdrawal effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Amisulpride can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other dopamine antagonists: may amplify antipsychotic effects and side‑effects. - Concomitant use with QT‑prolonging agents: increases risk of cardiac arrhythmias. - Combination with strong CYP2D6 inhibitors: can raise plasma levels of amisulpride.

Moderate Interactions (Monitor Closely): - Use with anticholinergic agents: may increase anticholinergic burden and cognitive effects. - Concurrent CNS depressants: may enhance sedation or respiratory depression. - Alcohol consumption: can intensify dizziness and orthostatic hypotension.